Saved Results

No results saved yet.

Enter a patient name and hit Save on a result.

Clinical calculator summary

ProMark® Proteomic Score

ProMark is an automated immunofluorescent assay that measures the levels of 8 signaling proteins in FFPE prostate tumor tissue.

Evidence-based context for fast calculator use

Purpose:
ProMark proteomic assay predicts aggressive pathology risk in prostate cancer biopsies to support active surveillance versus treatment decisions.
Population:
patients undergoing prostate cancer diagnostic, pathologic, recurrence, or molecular-risk assessment
Factors:
ProMark Score
Reference:
Blume-Jensen P, Berman DM, Rimm DL, et al. Development and clinical validation of an in situ biopsy-based multimarker assay for risk stratification in prostate cancer. Clin Cancer Res. 2015;21(11):2591-2600.
HomeProMark® Proteomic Score
Pin your most used calculators here by clicking the star in the dropdown.

ProMark® Proteomic Score

Clinical Context & Background

ProMark is an automated immunofluorescent assay that measures the levels of 8 signaling proteins in FFPE prostate tumor tissue. The resulting score (0 to 1) predicts the probability of finding adverse pathology (Gleason ≥4+3 or non-organ confined disease) at radical prostatectomy.
Primary Source EvidenceBlume-Jensen P, Berman DM, Rimm DL, et al. Development and clinical validation of an in situ biopsy-based multimarker assay for risk stratification in prostate cancer. Clin Cancer Res. 2015;21(11):2591-2600.
Formula Logic
Score 0.0 to 1.0 based on 8-protein signature.

Reference Data

ProMark ScoreRisk LevelRecommendation
< 0.33Low RiskSupports Active Surveillance
0.33 - 0.80Intermediate RiskIndividualized decision
> 0.80High RiskConsider Definitive Treatment

Clinical Workflow

Use, Interpret, And Continue The Patient Pathway

Expand for workflow guidance, limitations, examples, and related next steps.

When To Use

  • Use ProMark® Proteomic Score when proMark proteomic assay predicts aggressive pathology risk in prostate cancer biopsies to support active surveillance versus treatment decisions.
  • Confirm that the patient, diagnosis, disease phase, and available inputs match the cited model before calculation.

How To Interpret

  • Interpret the displayed result using the calculator-specific formula and reference table, spanning < 0.33 through > 0.80.
  • A boundary result should prompt input verification and clinical review rather than false precision.

What To Do Next

  • Confirm biopsy versus prostatectomy setting, PSA timing, grade group, clinical/pathologic stage, imaging, life expectancy, and treatment history.
  • Document the inputs, result, timing, and clinical context so the assessment can be reproduced.

Limitations

  • Diagnostic, post-prostatectomy, genomic, and recurrence tools must be used only at their intended decision point.
  • The result supports clinician judgment and does not independently determine treatment.

Validated Population

patients undergoing prostate cancer diagnostic, pathologic, recurrence, or molecular-risk assessment

How to apply this result

For a representative case, verify ProMark Score, calculate the result, and confirm that its classification matches the highlighted reference band before continuing the disease-specific pathway.

Prostate Cancer hubContinue to related calculators and clinical workflow resources.

Share This Calculator

Share:

Related Tools

D'Amico Risk ClassificationEpstein Criteria (Insignificant Cancer)PI-RADS™ v2.1 (Prostate MRI)

Frequently Asked Questions

When should ProMark® Proteomic Score be used?

Use it for patients undergoing prostate cancer diagnostic, pathologic, recurrence, or molecular-risk assessment when all required inputs and the intended clinical setting are confirmed.

Can ProMark® Proteomic Score determine treatment by itself?

No. Interpret the result with the cited evidence, complete clinical assessment, current guidelines, and patient-specific goals.

Evidence-based oncology decision support. Verify with clinical guidelines.